Shuyan Meng

Advances in cancer immunotherapy: historical perspectives, current developments, and future directions

Emerging mechanistic insights into liposomal stability: Full process management from production and storage to food application

A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC

RGD-targeted paramagnetic liposomes for early detection of tumor: In vitro and in vivo studies